C0737
Cilostazol
≥98% (HPLC), Phosphodiesterase III (PDE3) inhibitor, powder
别名:
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H27N5O2
化学文摘社编号:
分子量:
369.46
MDL编号:
UNSPSC代码:
41106305
PubChem化学物质编号:
NACRES:
NA.77
产品名称
Cilostazol, ≥98% (HPLC), powder
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
off-white
溶解性
DMSO: 10 mg/mL, clear
创始人
Otsuka Pharma
SMILES字符串
O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
基因信息
human ... PDE3A(5139), PDE3B(5140)
正在寻找类似产品? 访问 产品对比指南
一般描述
Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.
应用
Cilostazol has been used:
- to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
- in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
- to induce adenosine triphosphate (ATP) release in white adipocytes
生化/生理作用
Phosphodiesterase III (PDE3) inhibitor
特点和优势
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells
Munoz B, et al.
European Journal of Pharmacology, 616(1-3), 22-30 (2009)
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
Money SR, et al.
Journal of Vascular Surgery, 27(2), 267-275 (1998)
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial
Dawson DL, et al.
Circulation, 98(7), 678-686 (1998)
Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
商品
Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持